Does Tirzepatide Work Differently in Men and Women? What the Sex Difference Data Shows

One of the more consistent findings across the tirzepatide clinical program is also one of the least discussed with patients: women lose a larger percentage of their body weight on tirzepatide than men do. The difference appears in every one of the four SURMOUNT trials, it appears again in real world clinic data, and it grows over time rather than shrinking. It also has a plausible biological story behind it, involving drug exposure, sex hormones, and the rate at which the stomach empties.

This article lays out what the data shows, what the leading explanations are, where men and women differ on side effects, and what the gap does and does not mean for someone starting treatment. It is educational rather than individualized guidance, and the prescribing clinician is the right person to interpret any one person's response.

Do women lose more weight on tirzepatide than men?

Yes. Across the SURMOUNT program and in real world data, women consistently lose a larger percentage of starting body weight on tirzepatide than men, and the difference is large enough to be clinically meaningful rather than a statistical curiosity.

The clearest evidence comes from a post hoc analysis presented by Eli Lilly researchers at the European Association for the Study of Diabetes (EASD) annual meeting in Madrid in September 2024. It pooled the four SURMOUNT trials, which together enrolled 4,677 adults with obesity or overweight, 51 to 71 percent of them female depending on the trial, and followed them for 72 to 88 weeks. Across trials and doses, mean weight reductions ranged from 11.5 to 27.6 percent in females and 8.8 to 18.9 percent in males, and the highest mean reductions reported were 24.6 percent for females and 18.1 percent for males. Tirzepatide beat placebo by a wide margin in both sexes, so the point is not that men did poorly but that women did better.

The same pattern appears outside of trial conditions. A 2025 retrospective analysis published in Obesity examined 1,039 patients in the Mayo Clinic Health System who stayed on tirzepatide continuously for at least 12 months (57 percent women, mean age 56). Women had lost 14.8 percent of body weight at 15 months compared with 11.0 percent for men, which the authors described as approximately 41 percent greater total body weight loss. Female sex remained an independent predictor of greater loss after adjusting for age, dose, type 2 diabetes, prior obesity medication use, and concomitant medications that promote weight gain.

How big is the difference between men and women month by month?

The gap between men and women on tirzepatide is small at first and widens steadily with time on treatment. In the Mayo Clinic cohort, the sex difference was not statistically significant at 3 months, when women had lost 5.2 percent and men 4.8 percent, and it became significant from month 6 onward, with women at 9.0 percent versus 7.5 percent. By month 12 the figures were 13.7 percent versus 9.9 percent, and by month 15 they were 14.8 percent versus 11.0 percent.

That shape matters for interpretation. The early months on tirzepatide are spent at the 2.5 mg initiation dose and the first escalation steps, when nearly everyone loses at a similar modest rate. The divergence appears once people are on maintenance doses and the drug's full effect on appetite has had time to compound, so the sex difference is a difference in how far the curve goes rather than in whether tirzepatide starts working. The Aurelius article on the month by month timeline covers the shape of that curve in more detail.

Real world losses in this cohort were lower than SURMOUNT trial figures for both sexes, which is typical, because trial participants receive structured lifestyle support and are titrated to target doses on a fixed schedule, while clinic patients face insurance interruptions, dose holds for side effects, and less frequent follow up. About 70 percent of the Mayo cohort reached a dose of 10 mg or higher, and a higher final dose independently predicted greater loss.

Why do women respond more strongly to tirzepatide than men?

The most likely explanation is that women get more drug exposure per milligram and that estrogen amplifies the appetite effects of GLP-1 signaling in the brain, with sex differences in gastric emptying and food reward contributing on top. No single mechanism has been proven, and the EASD authors were explicit that more research is needed.

Body weight and drug exposure. Tirzepatide is dosed in fixed milligram steps of 2.5, 5, 7.5, 10, 12.5, and 15 mg regardless of body size. In the SURMOUNT pooled analysis, women weighed an average of 99.8 kg at randomization and men 115.2 kg, despite nearly identical BMI (38.2 versus 37.6). A 15 mg dose delivered to a 100 kg body produces higher blood concentrations than the same dose in a 115 kg body, and pharmacokinetic modeling of tirzepatide has suggested that males have lower exposure than females of the same weight even after body size is accounted for. Higher exposure plausibly means stronger appetite suppression and, as discussed below, more nausea.

Estrogen and GLP-1 signaling. Preclinical studies have shown that estrogen enhances the appetite suppressing and reward reducing effects of GLP-1 receptor agonists in the brain, increases energy expenditure, and reduces food motivated behavior. Estrogen receptors and GLP-1 receptors overlap in hypothalamic and brainstem regions that regulate hunger, and in rodent models the anorectic effect of GLP-1 agonism is blunted when estrogen signaling is removed. Whether menopausal hormone therapy changes the response to tirzepatide in humans is an active research question, and the Mayo authors noted that clinical data on this point are only beginning to emerge.

Gastric emptying and food reward. Women have slower baseline gastric emptying than men on average, and sex hormones influence both gut motility and the brain's reward response to palatable food. Because tirzepatide slows gastric emptying and dampens food reward, starting from a different baseline in each may shift how much additional effect the drug produces.

Behavioral and clinical factors. The Mayo authors also raised the possibility that women in their cohort differed from men in lifestyle adherence, motivation, or comorbidity burden. Men in the cohort were more likely to have type 2 diabetes, and diabetes was itself an independent predictor of smaller weight loss, a pattern that has been consistent across the GLP-1 class. Statistical adjustment reduces but does not eliminate this kind of confounding.

Does age change how well tirzepatide works?

Age has much less influence on tirzepatide response than sex does. In the Mayo Clinic cohort, patients aged 45 or younger lost modestly more at 15 months than those 60 and older (15.1 versus 12.3 percent), but age was not independently associated with weight loss once sex, dose, diabetes, and medication use were included in the model. The paper's title states the conclusion directly: sex, not age, predicts weight loss outcomes with tirzepatide.

This is consistent with the SURMOUNT trials, which enrolled adults across a wide age range and found tirzepatide effective in older and younger subgroups alike. Older adults do face separate considerations around muscle and bone preservation during rapid weight loss, which the prescribing clinician typically addresses through protein targets and resistance training rather than through dose changes, as discussed in the Aurelius article on tirzepatide in adults over 60.

Do men and women get different side effects on tirzepatide?

Women report more nausea and vomiting on tirzepatide than men. The EASD pooled analysis noted a numerically higher incidence of nausea and vomiting in females across the SURMOUNT trials, although the overall safety profile was otherwise similar between the sexes and consistent with what the program had already reported.

This fits with the exposure explanation above, because if women reach higher drug concentrations from the same milligram dose, they would be expected to experience both more appetite suppression and more of the dose dependent gastrointestinal effects. It is also the same pattern seen with semaglutide and the older GLP-1 receptor agonists, where women have consistently reported more gastrointestinal adverse events in both trials and pharmacovigilance databases.

In practice, this means women may benefit more often from a slower titration schedule, holding a dose for an extra four weeks or longer before stepping up, and from the standard nausea reduction habits of smaller meals, avoiding high fat foods around injection day, and staying hydrated. Men, by contrast, may tolerate escalation more easily and are more likely to reach the higher maintenance doses on schedule. Clinicians individualize titration for both sexes based on how the person is actually doing rather than on group averages.

Should men expect less from tirzepatide?

No. Men lost substantial weight in every SURMOUNT trial, with mean reductions up to 18.1 percent at the highest doses in the pooled analysis, which is well beyond what any older anti obesity medication achieved in either sex. The sex difference is a difference in degree between two strong responses, not a difference between responders and non responders.

Two points put the gap in perspective. First, men start heavier on average, so a smaller percentage can represent a similar number of pounds. A man starting at 254 pounds (115 kg) who loses 18 percent has lost about 46 pounds, while a woman starting at 220 pounds (100 kg) who loses 24 percent has lost about 53 pounds, so the percentage gap of six points becomes a gap of roughly seven pounds. Second, the outcomes that matter most clinically, such as A1c reduction, blood pressure, triglycerides, liver fat, and sleep apnea severity, improved substantially in men throughout the tirzepatide program, and several of those improvements depend more on absolute fat loss and visceral fat reduction than on the percentage on the scale.

For men who are losing more slowly than they expected, the more relevant questions are usually whether the dose has reached a therapeutic level, whether other medications are working against them, and whether diabetes is present, since each of those independently predicted smaller losses in the Mayo cohort. Sex is the one variable on that list that cannot be adjusted.

What does the sex difference mean for setting expectations?

The practical takeaway is that men and women on tirzepatide should be given slightly different reference points, and both should judge progress against a dose adjusted timeline rather than a single headline number. The table below summarizes how the two groups compare on the measures that come up most often in clinic.

For women, the trial averages of roughly 20 to 25 percent at the higher maintenance doses over 72 weeks are a reasonable frame, with the caveat that real world results run lower and that nausea during escalation is more common and worth planning for. For men, a frame of roughly 15 to 18 percent at the higher doses is more representative, with absolute pounds lost often comparable to women's because of the higher starting weight.

For both sexes, the first three months look nearly identical, so the early response checkpoint that clinicians use, commonly around 5 percent weight loss by week 12 to 16 on a therapeutic dose, applies equally. The difference emerges later and reflects how far treatment can go, which is a reason for patience during the maintenance phase rather than a reason to change course early.

The bottom line

Tirzepatide works well in both sexes, and it produces somewhat larger percentage losses in women. The pooled SURMOUNT data and the Mayo Clinic cohort agree on the direction and the rough size of the gap, and the most likely reasons are higher drug exposure per milligram in lighter bodies and estrogen's amplifying effect on GLP-1 signaling, with side effects following the same exposure logic. The difference emerges after the first few months rather than at the start, which makes it a reason for patience during maintenance rather than a reason to expect an early divergence.

Tirzepatide is a prescription medication with important safety considerations, including a boxed warning regarding thyroid C-cell tumors seen in rodent studies. Anyone weighing treatment should discuss their own starting point, dose plan, and other medications with a licensed clinician, who can set expectations that fit the individual rather than the group average.